Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2016 Feb;39(2):147-57.
doi: 10.1007/s40264-015-0374-9.

Safety of Dalbavancin in the Treatment of Skin and Skin Structure Infections: A Pooled Analysis of Randomized, Comparative Studies

Michael W Dunne  1 , George H Talbot  2 , Helen W Boucher  3 , Mark Wilcox  4   5 , Sailaja Puttagunta  6
Affiliations
Review

Safety of Dalbavancin in the Treatment of Skin and Skin Structure Infections: A Pooled Analysis of Randomized, Comparative Studies

Michael W Dunne et al. Drug Saf. 2016 Feb.

Abstract

Introduction: Dalbavancin is a new lipoglycopeptide that is active against Gram-positive pathogens, including methicillin-resistant Staphylococcus aureus. It has a half-life of 14.4 days, permitting intravenous treatment of acute bacterial skin and skin structure infections without the need for daily dosing.

Objective: The objective of these analyses was to compare the adverse event profile of dalbavancin with that of the comparator agents in the treatment of skin and skin structure infections.

Methods: Data on adverse events and laboratory assessments collected from 3002 patients enrolled in seven late-stage, randomized clinical trials were analyzed for patients receiving dalbavancin or a comparator antibiotic.

Results: Overall adverse event rates were similar or lower for patients receiving dalbavancin (799/1778; 44.9%) compared with those receiving comparator agents (573/1224; 46.8%, p = 0.012). The most common treatment-emergent adverse events were nausea, headache, diarrhea, constipation, vomiting, rash, urinary tract infection, pruritus, and insomnia. The duration and timing of the onset of adverse events were similar for patients receiving dalbavancin relative to the comparators.

Conclusion: Dalbavancin exhibits a favorable overall safety profile for treatment of acute bacterial skin and skin structure infections due to Gram-positive bacteria.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
Flow chart of patients included in safety and efficacy analyses. ABSSSI acute bacterial skin and skin structure infection, cSSSI complicated skin and skin structure infection, d/c patients discontinued from the study, uSSSI uncomplicated skin and skin structure infection
Fig. 2
Fig. 2
Duration of adverse events
Fig. 3
Fig. 3
Day of onset of adverse events (AE). TEAE treatment-emergent AE
See this image and copyright information in PMC

References

    1. Pallin DJ, Egan DJ, Pelletier AJ, et al. Increased US emergency department visits for skin and soft tissue infections, and changes in antibiotic choices, during the emergence of community-associated methicillin-resistant Staphylococcus aureus. Ann Emerg Med. 2008;51(3):292–298. doi: 10.1016/j.annemergmed.2007.12.004. - DOI - PubMed
    1. David MZ, Daum RS, Bayer AS, et al. Staphylococcus aureus bacteremia at five U.S. Academic Medical Centers, 2008–2011: significant geographic variation in community-onset infections. Clin Infect Dis. 2014;59(6):798–807. doi: 10.1093/cid/ciu410. - DOI - PMC - PubMed
    1. Liu C, Bayer A, Cosgrove SE, et al. Clinical practice guidelines by the Infectious Diseases Society of America for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children. Clin Infect Dis. 2011 - PubMed
    1. Daum RS. Clinical practice. Skin and soft-tissue infections caused by methicillin-resistant Staphylococcus aureus. N Engl J Med. 2007;357(4):380–390. doi: 10.1056/NEJMcp070747. - DOI - PubMed
    1. Dorr MB, Jabes D, Cavaleri M, et al. Human pharmacokinetics and rationale for once-weekly dosing of dalbavancin, a semi-synthetic glycopeptide. J Antimicrob Chemother 2005;55(Suppl 2): ii25–30. - PubMed

Publication types

MeSH terms

LinkOut - more resources